LLY — ELI LILLY & Co catalysts
Next verified catalyst
2026-12-01 — A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemother · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by
Phase 2 · Nausea, Vomiting |
LLY ELI LILLY & Co | LY3537021, Background Chemotherapy |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-02 (month) in 3mo
ESTIMATED |
READOUT
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in C
Phase 2 · Glioma |
LLY ELI LILLY & Co | Abemaciclib, Temozolomide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-02 (month) in 3mo
ESTIMATED |
READOUT
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040
Phase 3 · Obesity, Overweight |
LLY ELI LILLY & Co | Orforglipron |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-02 (month) in 3mo
ESTIMATED |
READOUT
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid R
Phase 2 · Smoking |
LLY ELI LILLY & Co | Brenipatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Comb
Phase 2 · Obesity, Overweight |
LLY ELI LILLY & Co | Macupatide, Eloralintide, Macupatide Pla |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceride
Phase 2 · Severe Hypertriglyceridemia |
LLY ELI LILLY & Co | Solbinsiran |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|